Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
Moodys
Medtronic
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,592,339

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,592,339 protect, and when does it expire?

Patent 7,592,339 protects XARELTO and is included in one NDA.

This patent has eighty-four patent family members in forty-six countries.

Summary for Patent: 7,592,339
Title:Substituted oxazolidinones and their use in the field of blood coagulation
Abstract: The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR00001## processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Inventor(s): Straub; Alexander (Wuppertal, DE), Lampe; Thomas (Wuppertal, DE), Pohlmann; Jens (Wuppertal, DE), Rohrig; Susanne (Essen, DE), Perzborn; Elisabeth (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Pernerstorfer; Joseph (Wuppertal, DE)
Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE)
Application Number:11/460,529
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,592,339
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,592,339

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-004 Oct 11, 2018 RX Yes No   Start Trial   Start Trial REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No   Start Trial   Start Trial REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No   Start Trial   Start Trial PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No   Start Trial   Start Trial TREATMENT OF PULMONARY EMBOLISM (PE)   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No   Start Trial   Start Trial REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
AstraZeneca
Express Scripts
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.